Immunotherapy Side Effects in Melanoma Treatment

Immunotherapy has transformed melanoma treatment, but it comes with a distinct set of side effects that differ sharply from those of traditional chemotherapy. Instead of hair loss and nausea from drugs killing fast-dividing cells, immunotherapy’s side effects stem from an overactivated immune system attacking the body’s own tissues. These immune-related adverse events can affect virtually any organ, from the skin and gut to the thyroid, liver, lungs, and even the heart and nervous system. Most are mild to moderate and manageable, but severe reactions requiring treatment interruption or hospitalization occur in a meaningful fraction of patients, particularly those on combination regimens.

What Makes Immunotherapy Side Effects Different

The checkpoint inhibitors used in melanoma work by releasing the brakes on the immune system. Drugs like nivolumab and pembrolizumab block a protein called PD-1, while ipilimumab blocks CTLA-4. Both pathways normally prevent immune cells from attacking healthy tissue. When those checkpoints are blocked, the immune system mounts a stronger attack against cancer cells, but it can also turn on normal organs. The resulting side effects are fundamentally inflammatory in nature, driven by T cells, autoantibodies, and inflammatory signaling molecules rather than the direct cellular toxicity of chemotherapy.¹

This mechanism means that immunotherapy side effects can look a lot like autoimmune diseases. A patient might develop something resembling rheumatoid arthritis, inflammatory bowel disease, or thyroiditis, sometimes temporarily and sometimes permanently. The range of possible effects is unusually broad compared with older cancer therapies, and the unpredictability of which organ gets targeted is one of the trickier aspects of managing these drugs.

The Most Common Side Effects

Skin reactions are the side effects you’re most likely to encounter. A systematic review and meta-analysis of melanoma patients on immunotherapy found that mild-to-moderate itching occurred in about 24% of patients, rash in about 21%, and vitiligo-like depigmentation in about 10%.² Skin side effects from CTLA-4 inhibitors tend to show up earlier, within about three to six weeks of starting treatment, while those from PD-1 inhibitors can appear anywhere from two to ten months in. Severe skin reactions like toxic epidermal necrolysis, where the skin essentially blisters and peels off in sheets, are rare but documented.³

Gastrointestinal side effects, particularly diarrhea and colitis, are another common category. These range from loose stools that can be managed at home to severe inflammation of the colon requiring hospitalization and potent immunosuppressive drugs. Colitis patterns seen under the microscope vary, with some resembling acute inflammatory bowel disease and others looking more like microscopic colitis.⁴ Severe colitis requiring treatment with anti-TNF drugs like infliximab is relatively uncommon in real-world practice, occurring in roughly 1% of advanced melanoma patients, mostly in those receiving ipilimumab.⁵

Endocrine problems round out the most frequent category. The thyroid is the most commonly affected gland, often developing inflammation that leads first to an overactive phase and then to permanent underactivity requiring lifelong thyroid hormone replacement. Inflammation of the pituitary gland, called hypophysitis, is another well-known pattern, especially with ipilimumab. Less commonly, immunotherapy can trigger type 1 diabetes or adrenal insufficiency.⁶ Most endocrine side effects are manageable with hormone replacement, and treatment can often continue as long as the hormonal issue is addressed. The exception is when the pituitary-adrenal axis is involved, which can become life-threatening if missed.⁷

Combination Therapy Raises the Stakes

Many advanced melanoma patients are now treated with a combination of nivolumab and ipilimumab, which improves tumor response rates and survival but substantially increases the risk of side effects. In a pooled analysis, about 55% of patients on the combination developed severe (grade 3 or 4) treatment-related adverse events, and roughly 36% had to stop treatment because of toxicity.⁸ These severe events occurred earlier than they typically do with either drug alone, though the rates at which they eventually resolved were similar.

Dosing matters within the combination. A meta-analysis found that the incidence of serious adverse events was significantly lower when the nivolumab dose was higher relative to ipilimumab, compared with the reverse ratio.⁹ This is one reason treatment protocols have evolved over time, adjusting the balance between the two drugs to try to preserve efficacy while reducing toxicity. Even so, treatment-related endocrine problems from the combination frequently require long-term medications that continue well after the immunotherapy course is finished.¹⁰

When Side Effects Appear and How Long They Can Last

Most severe immune-related adverse events show up within the first seven months of treatment. A retrospective study of 79 cases of severe (grade 3-4) events found that 75% occurred before the seven-month mark.¹¹ But that still leaves a tail of late arrivals. That same study documented severe events occurring more than two years into treatment, including a case of heart inflammation 759 days after starting and a case of liver inflammation at nearly four years.

What makes the timing issue especially tricky is that side effects can appear even after immunotherapy has been stopped. A large study found that the median time from starting treatment to a hospital admission for a side effect was about 2.7 months, but roughly 11% of patients were admitted more than a year after their first dose.¹² A separate study specifically looking at “delayed immune-related events” after treatment discontinuation found a median off-treatment interval of six months before a new immune side effect appeared, with some cases manifesting as late as 28 months after the last dose.¹³ These delayed events spanned endocrine, neurologic, gastrointestinal, lung, heart, joint, and skin involvement. The practical takeaway is that both patients and doctors need to maintain awareness of potential immune-related symptoms long after the infusions have ended.

Rare but Serious Reactions

Beyond the common skin, gut, and endocrine categories, immunotherapy can cause inflammation in organs that are harder to diagnose and more dangerous. A study of nearly 500 melanoma patients treated with PD-1 inhibitors catalogued side effects affecting the nervous system, lungs, muscles, heart, blood, and eyes. Some of the events had not been widely reported before, including specific patterns of nerve inflammation, cardiac arrhythmias, cardiac arrest, and muscle weakness syndromes like myasthenia gravis.¹⁴ Imaging studies in melanoma patients undergoing immunotherapy have also shown lung inflammation (pneumonitis), pituitary gland swelling, enlarged lymph nodes mimicking sarcoidosis, and muscle inflammation, all of which can range from incidental findings on a scan to clinically serious problems.¹⁵

Myocarditis, or inflammation of the heart muscle, deserves special mention because while uncommon, it carries a high fatality rate when it does occur. Neurologic complications like encephalitis, peripheral nerve damage, and inflammation of the membranes around the brain and spinal cord are similarly rare but can be severe and difficult to treat. The key message with these uncommon events is that any new or unexplained symptom during or after immunotherapy warrants medical attention, even if it seems unrelated to cancer treatment.

Side Effects That Signal the Treatment Is Working

One of the more counterintuitive aspects of immunotherapy side effects is that developing them appears to be linked to better cancer outcomes. A systematic review and meta-analysis of melanoma patients found that those who experienced immune-related adverse events had substantially longer survival compared with those who did not. Median overall survival was roughly 15 months in patients with side effects versus about 9 months in those without them, and response rates to treatment were also higher in the side-effect group.¹⁶

Vitiligo-like depigmentation, where patches of skin lose their color, is the most striking example. Because melanoma arises from pigment-producing cells called melanocytes, when the immune system attacks both the tumor and normal melanocytes, the resulting skin lightening is essentially visible evidence that the immune response is targeting melanoma-related cells. A systematic review found that patients who developed vitiligo had two to four times less risk of disease progression and death compared with those who didn’t.¹⁷ An Italian study of melanoma patients who developed vitiligo during checkpoint inhibitor treatment reported an overall response rate of 73%, and more than 80% were still alive three years after the depigmentation appeared.¹⁸

This correlation doesn’t mean patients should hope for severe side effects or that a lack of side effects means the treatment isn’t working. But it does change how some side effects are perceived clinically, and it’s worth knowing about if you’re the one noticing new white patches on your skin.

How Side Effects Are Managed

Mild side effects like low-grade rash or itching are typically treated with topical creams or antihistamines, and immunotherapy continues. Moderate side effects often call for a temporary pause in treatment and a course of oral corticosteroids. Severe reactions trigger a longer hold or permanent discontinuation, with high-dose intravenous steroids as the frontline treatment.

The timing of steroid use matters more than you might expect. A study of melanoma patients found that steroid exposure overall was actually associated with better outcomes, but early steroid use, within four weeks of starting immunotherapy, was linked to significantly shorter time before disease progression compared with steroids given later.¹⁹ The likely explanation is that early steroid use may blunt the initial immune activation that makes the treatment work, while later steroid use to manage established side effects doesn’t have the same dampening effect on anticancer immunity.

When steroids fail to resolve severe colitis, infliximab (an anti-TNF antibody) is a standard second-line option, and reassuringly, data suggest that using infliximab for severe colitis does not appear to worsen cancer outcomes.²⁰ For the subset of patients whose colitis doesn’t respond to steroids or infliximab, vedolizumab, an antibody that targets gut-specific immune pathways, has shown promise in case reports and small series.²¹²²

Long-Term and Permanent Side Effects

A question that often doesn’t get enough attention is what happens after immunotherapy ends. In one study of melanoma patients, 41% developed permanent side effects, meaning effects that never fully resolved. About a third of all patients were still on medication for ongoing immune-related problems six months or more after finishing treatment, most commonly thyroid hormone replacement or oral steroids.²³

Quality-of-life research on melanoma survivors treated with checkpoint inhibitors gives a mixed picture. One study found that overall quality of life was good, with a median global health score of 83%. But when you drill into the details, 40% of long-term survivors reported some degree of anxiety or depression, about 31% had ongoing pain or discomfort, and fatigue was a persistent problem, with roughly 28% reporting being easily fatigued.²⁴ Joint and muscle aching were the most frequently reported lingering symptoms. Another study found that melanoma survivors who had been through immunotherapy scored significantly lower on physical, social, and overall health functioning compared with the general population.²⁵

These numbers deserve context. Many of these patients had stage 4 melanoma that would have been a near-certain death sentence a decade ago. A quality-of-life score lower than the general population but paired with being alive and cancer-free is a trade-off most patients accept willingly. Still, the persistence of fatigue, joint pain, and the need for ongoing medications is something to plan for rather than be surprised by.

Restarting Immunotherapy After a Severe Reaction

Sometimes a patient’s melanoma progresses after they had to stop immunotherapy due to a severe side effect, and the question becomes whether it’s safe to try again. In a review of patients who were rechallenged with anti-PD-1 therapy after a prior severe reaction, about half experienced some degree of immune-related adverse events, but only 18% had a recurrence of the same type of side effect they’d had before. About 18% developed severe (grade 3-5) toxicity on rechallenge, and 30% ultimately had to stop treatment again. Patients who were still on steroids when they restarted immunotherapy had higher rates of toxicity (55%) compared with those who had fully tapered off (31%).²⁶

Rechallenge is not off the table, but it requires careful risk-benefit assessment. Both single-agent and combination rechallenge can provide survival benefits for patients who respond.²⁷ The decision depends heavily on the severity and type of the initial reaction, what alternative treatments are available, and how urgently the cancer needs to be controlled.

Pre-existing Autoimmune Conditions

Patients with a pre-existing autoimmune disease were excluded from most of the original clinical trials of checkpoint inhibitors, which left doctors with limited guidance. Real-world data has since filled in some of the gaps. A large cohort study found that the rate of severe side effects in patients with autoimmune disease was comparable to those without: about 17% for anti-PD-1 monotherapy and 44% for the combination, versus 13% and 48% respectively in patients without autoimmune disease. Response rates and survival were also similar between the two groups.²⁸

That said, about a third of patients with a pre-existing autoimmune condition experienced a flare of their underlying disease. Inflammatory bowel disease patients were particularly susceptible to immunotherapy-induced colitis, and patients already on immunosuppressive drugs had a higher risk of flare.²⁹ In a smaller ipilimumab study, about 29% had a flare, but more than half of all patients experienced neither a flare nor any new immune-related side effect.³⁰ The bottom line is that having an autoimmune condition doesn’t automatically disqualify you from immunotherapy, but it does call for closer monitoring and a lower threshold for early intervention.

Age and Side Effect Risk

Given that melanoma is more common in older adults, the question of whether age changes the side effect profile is practical. The evidence is somewhat reassuring. Studies of melanoma patients across different age groups have found similar grades and incidence of the most commonly reported side effects, including diarrhea, skin eruptions, and endocrine problems. However, some rarer complications like kidney inflammation and meningitis were reported specifically in older patients and not seen in younger groups.³¹ Older patients often have more comorbidities and less physiologic reserve, which can make a given side effect harder to tolerate and recover from even if the incidence rate is similar.

Predicting Who Will Get Hit Hardest

One of the most active areas of research is trying to predict which patients will develop immune-related side effects before they happen. The gut microbiome has emerged as a promising tool. Certain patterns in the composition and function of gut bacteria appear to correlate with both treatment response and the likelihood of developing side effects.³² A study that developed a prediction model using 14 microbial features from stool samples was able to distinguish patients who would go on to develop immune-related adverse events from those who wouldn’t with high accuracy.³³

These tools are not yet ready for routine clinical use, but they represent a future where immunotherapy could be personalized not just for efficacy but for safety. If a stool test before treatment could flag a patient as high-risk for severe colitis, preemptive strategies or adjusted dosing could potentially prevent the worst outcomes. For now, the most practical monitoring approach remains regular blood work for liver and thyroid function, clear patient education about symptoms to watch for, and a medical team experienced in recognizing and managing immune-related complications quickly.